The Advanced Glycation End Product Nε-Carboxymethyllysine Is Not a Predictor of Cardiovascular Events and Renal Outcomes in Patients With Type 2 Diabetic Kidney Disease and Hypertension
暂无分享,去创建一个
L. Hunsicker | G. Wolf | U. Ott | S. Franke | M. Busch | A. Brandstädt | J. Gerth | G. Stein
[1] D. Daleke,et al. The role of oxidative stress in diabetic complications , 2007, Cell Biochemistry and Biophysics.
[2] J. Nagy,et al. Serum carboxymethyllysine predicts mortality in hemodialysis patients. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[3] Reindert Graaff,et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. , 2005, Journal of the American Society of Nephrology : JASN.
[4] S. Genuth,et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. , 2005, Diabetes.
[5] H. Stopper,et al. Two immunochemical assays to measure advanced glycation end-products in serum from dialysis patients , 2005, Clinical chemistry and laboratory medicine.
[6] Yusuke Suzuki,et al. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[7] M. Pfeffer,et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. , 2004, Kidney international. Supplement.
[8] H. Parving,et al. Progression of nephropathy in type 2 diabetic patients. , 2004, Kidney international.
[9] R. de Caterina,et al. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. , 2004, Cardiovascular research.
[10] G. Lang,et al. Elevated serum levels of Nε-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema , 2004, Diabetologia.
[11] U. Ott,et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. , 2004, Kidney international.
[12] R. Gans,et al. Simple non-invasive assessment of advanced glycation endproduct accumulation , 2004, Diabetologia.
[13] J. Uribarri,et al. Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[14] G. Müller,et al. Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA. , 2003, Diabetes care.
[15] V. D’Agati,et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. , 2003, The American journal of pathology.
[16] M. Pfeffer,et al. Cardiovascular Outcomes in the Irbesartan Diabetic Nephropathy Trial of Patients with Type 2 Diabetes and Overt Nephropathy , 2003, Annals of Internal Medicine.
[17] T. Wendt,et al. Are advanced glycation end products cardiovascular risk factors in patients with CRF? , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[18] M. Nangaku,et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. , 2002, Journal of the American Society of Nephrology : JASN.
[19] C. Wanner,et al. Advanced glycation end products and mortality in hemodialysis patients. , 2002, Kidney international.
[20] J. Nagy,et al. N(epsilon)-(carboxymethyl)lysine levels in patients with type 2 diabetes: role of renal function. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[21] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[22] J. Baynes,et al. Glycoxidation and lipoxidation in atherogenesis. , 2000, Free radical biology & medicine.
[23] M. F. Weiss,et al. Mechanisms for the formation of glycoxidation products in end-stage renal disease. , 2000, Kidney international.
[24] E. Lewis,et al. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[25] M Ishii,et al. [The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.
[26] S. Genuth,et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Contro , 1999, Diabetes.
[27] A. Levey,et al. A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation , 1999, Annals of Internal Medicine.
[28] C van Ypersele de Strihou,et al. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. , 1999, Kidney international.
[29] J. Baynes,et al. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.
[30] T. Miyata,et al. Autoxidation products of both carbohydrates and lipids are increased in uremic plasma: is there oxidative stress in uremia? , 1998, Kidney international.
[31] R. Ziegler,et al. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. , 1998, Cardiovascular research.
[32] E. Diamandis,et al. The serum concentration of the advanced glycation end-product Nε-(carboxymethyl)lysine is increased in uremia: Technical Note , 1997 .
[33] T. Lyons,et al. Age-dependent increase in ortho-tyrosine and methionine sulfoxide in human skin collagen is not accelerated in diabetes. Evidence against a generalized increase in oxidative stress in diabetes. , 1997, The Journal of clinical investigation.
[34] R. Bucala,et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[35] T. Miyazaki,et al. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. , 1997, The Journal of clinical investigation.
[36] E. Schleicher,et al. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging. , 1997, The Journal of clinical investigation.
[37] D. Hricik,et al. Disparate changes in plasma and tissue pentosidine levels after kidney and kidney-pancreas transplantation. , 1996, Clinical transplantation.
[38] C van Ypersele de Strihou,et al. Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine. , 1996, Journal of the American Society of Nephrology : JASN.
[39] T. Lyons,et al. The Advanced Glycation End Product, N-(Carboxymethyl)lysine, Is a Product of both Lipid Peroxidation and Glycoxidation Reactions (*) , 1996, The Journal of Biological Chemistry.
[40] J. Baynes,et al. New biomarkers of Maillard reaction damage to proteins. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[41] F. Harrell,et al. Regression modelling strategies for improved prognostic prediction. , 1984, Statistics in medicine.